1: Letsch M, Schally AV, Stangelberger A, Groot K, Varga JL. Antagonists of

growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced

by androgen deprivation in human MDA-Pca-2b prostate cancers. Eur J Cancer. 2004; 40:436-44.



2: Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P,

Halmos G. Inhibitory effect of antagonists of bombesin and growth

hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness

of PC-3 human prostate cancer in nude mice. Clin Cancer Res. 2005 Jan 1;11:49-57.



3: Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ,

Zarandi M. Antagonists of growth hormone releasing hormone (GHRH) and of

bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF,

bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human

androgen-independent prostate cancers. Prostate. 2005;64:303-15.



4: Stangelberger A, Schally AV, Letsch M, Szepeshazi K, Nagy A, Halmos G,

Kanashiro CA, Corey E, Vessella R. Targeted chemotherapy with cytotoxic bombesin

analogue AN-215 inhibits growth of experimental human prostate cancers. Int J

Cancer. 2006;118:222-9.



5: Stangelberger A, Schally AV, Nagy A, Szepeshazi K, Kanashiro CA, Halmos G.

Inhibition of human experimental prostate cancers by a targeted cytotoxic

luteinizing hormone-releasing hormone analog AN-207. Prostate. 2006 Feb 1;66:200-10.



6: Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, Hammann BD,

Armatis P, Kanashiro CA. Inhibition of human androgen-independent PC-3 and DU-145

prostate cancers by antagonists of bombesin and growth hormone releasing hormone

is linked to PKC, MAPK and c-jun intracellular signalling. Eur J Cancer. 2005;41:2735-44.



7: Djavan B, Rocco B, Stangelberger A, De Cobelli O, Marberger M. Is the era of

prostate-specific antigen over? BJU Int. 2007 Jul;100 Suppl 2:8-10. Review.



8: Stangelberger A, Schally AV, Zarandi M, Heinrich E, Groot K, Havt A, Kanashiro

CA, Varga JL, Halmos G. The combination of antagonists of LHRH with antagonists

of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35

prostate cancers. Prostate. 2007;67:1339-53.



9: Stangelberger A, Schally AV, Djavan B. New treatment approaches for prostate

cancer based on peptide analogues. Eur Urol. 2008 May;53:890-900. Review.


10: Margreiter M, Stangelberger A, Valimberti E, Herwig R, Djavan B. Biomarkers

for early prostate cancer detection. Minerva Urol Nefrol. 2008;60:51-60. Review.


11: Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev

Urol. 2008 Spring;10:111-9.



12: Stangelberger A, Schally AV, Rick FG, Varga JL, Baker B, Zarandi M, Halmos G.

Inhibitory effects of antagonists of growth hormone releasing hormone on

experimental prostate cancers are associated with upregulation of wild-type p53

and decrease in p21 and mutant p53 proteins. Prostate. 2012;:555-65.


13: Stangelberger A, Riedl CR, Susani M. Osteosarcoma of the prostate after radiotherapy].

Aktuelle Urol. 2012 Dec;43(6):409-11. German